GLP1R and pancreatic neoplasm: The HLTs associated with DPP-4 inhibitors and GLP-1 receptor agonists indicated pancreatic events (“Acute and chronic pancreatitis,” “Pancreatic neoplasms,” “Pancreatic neoplasms malignant (excl islet cell and carcinoid),” and “Pancreatic disorders NEC”), gastrointestinal events (“Benign neoplasms gastrointestinal (excl oral cavity)” and “Gastrointestinal stenosis and obstruction NEC”), and cholecystic events (“Cholecystitis and cholelithiasis”).